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A B s T r A C T
Background: Erysipelas is a distinctive type of superficial 
cellulitis of the skin with prominent lymphatic involvement, 
generally caused by group A streptococci. A substantial 
proportion of patients experience recurrences of erysipelas, 
and this may be a reason to install prophylactic antibiotic 
treatment. despite such prophylaxis, further recurrences 
are occasionally encountered. 
objectives: To investigate recurrences of erysipelas during 
prophylactic antibiotic treatment and to delineate the 
reasons for such failure. 
Methods: retrospective chart review of 117 adult patients 
with episodes of erysipelas known in our institution 
between 1990 and 2004. 
results: recurrent episodes of erysipelas, despite 
prophylactic treatment, were found in eight patients. our 
analysis indicated noncompliance, incorrect selection and 
insufficient dosing of antibiotics, and causative pathogens 
other than streptococci as demonstrable causes of the 
recurrence of erysipelas. in three patients, a reason for 
failure could not be identified. 
Conclusions: in a minority of cases, erysipelas recurs 
despite antibiotic prophylaxis. Based on these cases, we 
first recommend that all efforts are made to (re)confirm the 
diagnosis of erysipelas and search for the causative micro-
organism. Based on this information, the right antibiotic 
with adequate dosing and timing can be selected. The issue 
of compliance with the prophylactic treatment should be 
addressed and finally, the clinician should be aware that 
prophylaxis does not prevent erysipelas in all cases.
K E Y w o r d s
Antibiotic prophylaxis, erysipelas, prevention, recurrent 
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i N T r o d u C T i o N
Erysipelas is an acute inflammation of the skin, with 
marked involvement of cutaneous lymphatic vessels. It 
is a clinically recognisable entity, with sudden onset of 
fever and a painful erythematous swollen lesion, sharply 
demarcated from the normal skin. Erysipelas is most 
commonly caused by b-haemolytic streptococci of group 
A, less so by group B, C, or G streptococci, and occasionally 
by Staphylococcus aureus.1,2 In many patients, factors are 
present that facilitate the development of erysipelas. The 
major risk factors in erysipelas are disruption of the skin 
and lymphoedema.3 Erysipelas can be treated successfully 
with narrow-spectrum penicillins, such as benzylpenicillin 
and feneticillin. Patients who are allergic to penicillin may 
be treated effectively with macrolides.
The recurrence rate of erysipelas is high: nearly 30% has 
been noted within a two to four year period.4 Unfortunately, 
once erysipelas occurs, damage to the cutaneous lymph 
vessels often leads to susceptibility for further relapses. 
To prevent a vicious circle of recurrent erysipelas and 
vulnerability to subsequent episodes, long-term antibiotic 
prophylaxis is advocated. Studies have suggested an effect 
of such prophylaxis, using various antibiotic regimens.4-7
A neglected aspect in studies on prophylaxis for erysipelas 
is that a few patients still have attacks of erysipelas during 
antibiotic prophylaxis.7,8 In line with this notion, we have 
encountered patients with recurrent erysipelas despite 
antibiotic prophylaxis. In this paper, we review these cases 
and examine the reasons for failure of prophylaxis.
p A T i E N T s  A N d  M E T h o d s
Patients with one or more episodes of erysipelas during 
antibiotic prophylaxis were identified and retrospectively 
analysed to examine the incidence of recurring erysipelas 
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despite prophylactic antibiotic treatment and the factors 
associated with this failure. Patients were identified by 
searching two databases for the clinical diagnosis of 
erysipelas: the first database contains data on infectious 
disease consultations performed in our university medical 
centre between 1990 and 2004; the second contains the 
diagnoses of patients at the outpatient clinic for internal 
medicine from 1999 until 2003. In addition, infectious 
disease specialists were asked whether they were aware of 
additional patients.
From the charts of patients with attacks of erysipelas 
during antibiotic prophylaxis, the following data were 
collected: 1) personal characteristics: gender, age, weight; 
2) underlying diseases and/or factors predisposing for 
erysipelas; 3) attacks of erysipelas before prophylactic 
treatment; 4) results of diagnostic tests, such as cultures, 
antistreptolysin titres and anti-DNAse B; 5) treatment of 
the episodes of erysipelas; 6) prophylactic regimens; 7) the 
effect of the antibiotic prophylaxis.
r E s u l T s
In this study, 117 patients with erysipelas were identified. 
Five patients had an attack despite antibiotic prophylaxis. 
Three more patients were retrieved from infectious 
diseases specialists. The characteristics of these eight 
patients, the sites of erysipelas, and underlying conditions 
are provided in table 1.
The phenomenon of recurrent erysipelas under antibiotic 
prophylaxis will further be described on the basis of three 
illustrative cases.
patient C
This 29-year-old male had suffered from several episodes 
of erysipelas affecting the right leg since the age of 17. At 
15 years, he underwent an epiphysiodesis of the femur 
and tibia of his right leg to correct a difference in length. 
He had been treated with benzathine penicillin 1.2 MU 
intramuscularly every four weeks as prophylaxis. Despite 
this treatment, frequent attacks of erysipelas recurred. It 
turned out that relapses occurred shortly before the next 
injection was planned.
At the age of 20, the patient was hospitalised for another 
episode of erysipelas, which was treated with penicillin 
G. On this occasion, interdigital mycosis was found as a 
potential portal of entry. In an attempt to reduce the risk of 
another attack, antimycotic treatment and elastic stockings 
were prescribed, but despite this, episodes of erysipelas 
still recurred. The attacks responded well to therapy with 
roxitromycin. 
The patient was first seen at our department at the age of 
22. He was put on a prophylactic regimen of benzathine 
penicillin 1.2 MU every two weeks and this preventive 
treatment was successfully continued for two years. Six 
months after stopping, a new episode occurred, and the 
two-weekly preventive regimen was reinstituted. Despite the 
prophylaxis, a new attack occurred three months later. This 
episode probably occurred because the penicillin injection 
was delayed until 3.5 weeks after the previous dose.
The next episode of erysipelas developed 16 days after 
the injection of benzathine penicillin. After treatment, a 
prophylactic regimen of injections strictly administered 
every two weeks was installed. This prevented recurrences 
for 2.5 years. On the patient’s request, the frequency of 
administration was again reduced to every three weeks 
and this led to new episodes of erysipelas. Antibiotic 
prophylaxis every two weeks has prevented further attacks 
of erysipelas, for one year of follow-up.
patient E
This 24-year-old female experienced a minor trauma of 
her chin at the age of five. The first episode of erysipelas 
at the age of 14 affected her chin and lower lip. During the 
following years she had several attacks of erysipelas. After 
her second hospitalisation at the age of 18, she received 
Koster, et al. Recurrent erysipelas despite antibiotic prophylaxis.
Table 1. Patients characteristics
patient Age 
(years)
sex weight
(kg)
location underlying condition site of entry Age at first 
episode
(years)
Age at start of 
prophylaxis
(years)
A 45 m 113 Right and left leg Trauma: spinal cord lesion, 
multiple fractures left leg
Intertrigo 33 39
B 56 m  – Left leg Spinal muscular atrophy, 
fracture left femur
47 52
C 29 m 108 Right leg Epiphysiodesis right leg Dermatomycosis 17 19
D 53 f 86 Left arm Post-breast cancer surgery Eczema 44 47
E 24 f 72 Face Trauma chin 14 18
F 38 m 74 Right and left leg Short-bowel syndrome, arterial 
insufficiency right leg
Intertrigo 34 35
G 55 f 62 Right arm Post-breast cancer surgery Skin lesion 45 53
H 39 f 63 Face, neck Recurrent herpes simplex Herpetic lesions 29 30
91
M A R C H  2 0 0 7 ,  V o l .  6 5 ,  N o .  3
prophylactic treatment, consisting of benzathine penicillin 
1.2 MU intramuscularly every four weeks. 
She remained free from episodes of erysipelas for 11 months 
until a new attack at the same site occurred during antibiotic 
prophylaxis. During this episode, the serology was suggestive 
for a streptococcal origin: aspartate aminotransaminase 
(AST) (332 U ml-1) and anti-DNAse (B 879 U ml-1) were both 
elevated, whereas the antistaphylolysin titre was 0.71 U ml-1. 
She was referred to our clinic.
The prophylactic regimen was changed to clindamycin 
300 mg three times a day. Five months after starting with 
this regimen, another episode of erysipelas occurred. As 
the patient was not critically ill, we felt confident to try 
and see whether it was a dose or a resorption problem. So 
we switched to intravenous clindamycin 3 x 600 mg. The 
response to therapy with intravenous clindamycin was 
rapid. Hereafter, the dose of prophylactic treatment was 
raised to 300 mg four times a day. Measurement of serum 
clindamycin showed concentrations of 1.69 and 4.12 mg 
l-1, which are considered appropriate. Even with the higher 
oral dose of clindamycin, another episode of erysipelas 
occurred three months later. Prophylaxis was stopped, and 
nine months later, she again developed erysipelas.
patient g
This 55-year-old female was healthy until the age of 44, 
when breast cancer was diagnosed. A modified radical 
mastectomy with axillary lymph node dissection was 
performed. A year later, a tumour was found in her 
other breast, and a mastectomy with axillary lymph 
node dissection was performed followed by radiotherapy. 
Tamoxifen was continued for 2.5 years.
Since the second mastectomy, she experienced several 
episodes of erysipelas. These episodes would usually 
follow a small skin defect on the right hand and were 
characterised by a fiery red, sharply demarcated lesion 
on one side of the thorax and the right arm, high fever, 
and systemic toxicity. Response to treatment with either 
amoxicillin or flucloxacillin was rapid.
Five years after surgery, a reconstruction by a latissimus 
dorsi muscle flap combined with breast implants was 
performed, complicated by oedema of the right arm. 
The episodes of erysipelas increased in frequency. After 
multiple attacks, the patient was put on benzathine 
penicillin 1.2 MU intramuscularly every four weeks. The 
attacks decreased but were not completely prevented. 
Even injections given every two weeks did not prevent 
the episodes of erysipelas. There was no clear correlation 
between the time of injection and the occurrence of 
erysipelas. 
After stopping the prophylactic treatment, the frequency 
of erysipelas increased to once every one or two months. 
She was put on a prophylactic regimen of clindamycin 
600 mg twice daily, and several months later the dose was 
decreased to 600 mg once daily. This treatment prevented 
further episodes of erysipelas for three months, but 
thereafter breakthroughs occurred.
An overview of the cases of recurrent erysipelas during 
antibiotic prophylaxis is provided in table 2. In most cases, 
it is not possible to judge whether these recurrent episodes 
represent relapses from foci within the body or exogenous 
reinfections.
In a number of cases, a plausible explanation for the failure 
of prophylaxis and subsequent recurrences could be given 
on the basis of chart review. These were: 1) noncompliance; 
2) incorrect antibiotic; 3) other causative micro-organism; 
and 4) insufficient antibiotic concentration.
Noncompliance 
Two patients experienced an episode of erysipelas when 
they extended the interval time of the prophylactic regimes. 
Patient C exceeded the prophylactic schedule by 1.5 weeks, 
when erysipelas recurred. Patient A had a new attack of 
erysipelas ten weeks after the last injection.
incorrect antibiotic
Instead of benzathine penicillin, patient B received a 
combination of benzathine and procaine-benzylpenicillin. 
This agent only contains 0.6 MU of benzathine penicillin. 
Penicillin concentrations in serum are therefore only 
detectable for about one week.
other causative micro-organism
Although no culture samples could be obtained, it is likely 
that the recurrences in patients D and B during antibiotic 
prophylaxis were not caused by group A streptococci, but by 
Staphylococcus aureus. Patient D developed a skin infection 
of the left arm four days after the injection of benzathine 
penicillin. The infection responded to flucloxacillin. Patient 
B developed an attack of erysipelas one week after the 
injection of benzathine penicillin 1.2 MU. The initial 
treatment consisted of feneticillin 1000 mg four times 
a day. Despite an initial improvement, treatment was 
unsuccessful. After two weeks, the treatment was changed 
to clindamycin 600 mg three times a day, which led to an 
improvement.
insufficient antibiotic concentration
In three patients, the serum concentrations of the 
antibiotic agent were probably insufficient. Patient B 
received clarithromycin 250 mg daily to prevent further 
episodes of erysipelas. This did not prevent the episode 
1.5 weeks later. The recommended therapeutic dose for 
an adult should be at least 250 mg twice daily. Patients C 
and H experienced several episodes during prophylaxis 
with benzathine penicillin 1.2 MU. The occurrence of 
episodes of erysipelas occurred just before the dose was to 
Koster, et al. Recurrent erysipelas despite antibiotic prophylaxis.
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be administered, which may indicate insufficient levels of 
the antibiotic during the last phase of the administration 
interval. Indeed, in patient B injections every two weeks 
and in patient H every three weeks prevented relapses. 
No explanation
Recurrences of erysipelas during antibiotic prophylaxis in 
patients E, F, and G could not be explained. Furthermore, 
no explanation was available for one episode of erysipelas 
in patients C and D. 
d i s C u s s i o N
Our review of the literature and analyses of case reports 
clearly indicate that despite antibiotic prophylaxis, 
erysipelas still recurs.7,8 Recurrent erysipelas despite 
prophylaxis has gone unnoticed, because cases are rare. 
A survey in our tertiary care centre among 117 cases of 
erysipelas yielded eight such cases. It is not usually possible 
to judge whether these recurrent episodes represent 
relapses from foci within the body (e.g., within the 
lymphatic system) or exogenous reinfections.
The analysis of the reasons for failure of preventive therapy 
in our sample indicates that the recurrence of erysipelas had 
multiple causes: 1) noncompliance; 2) incorrect antibiotic; 
3) other causative micro-organism; 4) insufficient antibiotic 
concentrations. Importantly, in half of the cases, no valid 
explanation could be obtained. Thus, the reasons for failure 
of prophylaxis in these cases remain unclear. We tend to 
conclude that in such cases, erysipelas may recur despite 
concentrations of antibiotics that are otherwise considered 
adequate. We have not been able to find many similar cases 
in the literature.
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Table 2. Recurrences during antibiotic prophylaxis
reasons for failure of prophylaxis
patient re-
currence
Antibiotic dosage Time to 
recurrence
Treatment of 
erysipelas
Non-
compliance
incorrect 
antibiotic
other 
causative 
micro-
organism
insufficient 
antibiotic 
concen-
tration
No 
explana-
tion
A 1 benzathine 
penicillin
1.2 MU/ 
4 wk
15 mo penicillin, 
feneticillin
v
B 1 procaine 
penicillin
1.2 MU/ 
4 wk
   v
2 clarithromycin 250 
mg/day
1.5 wk  v
3 benzathine 
penicillin
1.2 MU/ 
3 wk
1 wk feneticillin 
failed
v
C 1 benzathine 
penicillin
1.2 MU/ 
4 wk
*   v
2 benzathine 
penicillin
1.2 MU/ 
2 wk
3.5 wk  v v
3 benzathine 
penicillin
1.2 MU/ 
2 wk
2 wk feneticillin v
4 benzathine 
penicillin
1.2 MU/ 
3 wk
  penicillin, 
feneticillin
v
D 1 benzathine 
penicillin
1.2 MU/ 
4 wk
2 wk flucloxacillin v
2 benzathine 
penicillin
1.2 MU/ 
3 wk
1.5 wk amoxicillin v
E 1 benzathine 
penicillin
1.2 MU/ 
4 wk
9 mo amoxicillin v
2 clindamycin 300 mg 
t.i.d.
  clindamycin  
iv
v
3 clindamycin 300 mg 
q.i.d.
  clindamycin  
iv
v
F 1 benzathine 
penicillin
1.2 MU/ 
4 wk
   v
G 1 benzathine 
penicillin
1.2 MU/ 
4 wk
   v
2 benzathine 
penicillin
1.2 MU/ 
2 wk
   v
H 1 benzathine 
penicillin
1.2 MU/ 
4 wk
9 mo penicillin ** v
* shortly before the next injection was planned; ** plus valaciclovir prophylaxis; wk = week; mo = month; t.i.d. = three times a day; 
q.i.d = 4 times a day. 
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An important question is whether evidence exists that 
antibiotic prophylaxis is effective in preventing recurrences 
of erysipelas. In the older literature, case reports suggested 
that prolonged antibiotic prophylaxis successfully reduces 
the frequency of attacks in all patients with recurrent 
erysipelas.8,9 In addition, several clinical studies have 
addressed this problem. In the study by Duvanel et al.5 
benzathine penicillin 2.4 MU every three weeks was given 
intramuscularly to 12 patients for six months, after the first 
attack of erysipelas. There where no recurrences during 
the period of prophylaxis, but after discontinuation of 
prophylaxis, three patients experienced a recurrence.
Jorup-Rönström et al.4 included 143 patients with 
erysipelas; 29% had recurrences during a follow-up 
period of two to four years. Only nine patients received 
antibiotic prophylaxis, which prevented further episodes 
of erysipelas. After the second recurrence, the calculated 
cost of prophylaxis with phenoxymethylpenicillin or 
erythromycin was only marginally lower then the cost of 
therapy for erysipelas attacks.
Kremer et al.6 studied erythromycin as a preventive 
antibiotic in 32 patients who had suffered two or more 
episodes of erysipelas or cellulitis during a follow-up period 
of 18 months. Only 11 of 36 patients were included because 
of recurrent erysipelas. There were no recurrences in the 
study group, compared with a relapse rate of 50% in the 
control group. 
Sjöblom et al.7 prescribed antibiotic prophylaxis to 20 patients 
with a history of two or more attacks of erysipelas. 
Phenoxymethylpenicillin was given in most cases. A few 
patients received erythromycin because of a known allergy 
to penicillin. Despite the antibiotic prophylaxis, two patients 
had a recurrence, compared with eight patients in the control 
group. The median follow-up period was 15 months.
Our study has a number of implications for clinicians 
dealing with recurrent erysipelas (summarised in table 3). 
First, we would recommend that the diagnosis is as certain 
as it can possibly be. Cultures and serology may be of 
help to ascertain the cause. Not only should the question 
be raised whether it is a streptococcal or a staphylococcal 
infection, but also more rare causes, such as Campylobacter 
jejuni, especially in patients with compromised host 
defences (e.g., hypogammaglobulinaemia) and 
Campylobacter fetus in patients with other underlying 
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Table 3. Recurrent erysipelas despite antibiotic 
prophylaxis
1. Check compliance
2. Reconsider diagnosis (Staphylococcus aureus, Campylobacter 
species)
3. Consider shortening the dosing interval (benzathine penicillin) 
or raising the dose of oral prophylaxis
4. Change regimen, e.g., to clindamycin
illnesses,10-12 should be considered. Secondly, the clinician 
should make sure that the correct antibiotic is selected, 
based on the most likely causative micro-organism. Thirdly, 
dosing and timing of antibiotic prophylaxis is of great 
relevance. A problem is that the penicillin concentrations 
needed for adequate prophylaxis are not known. From 
a theoretical point of view, it could be argued that the 
protective serum penicillin concentrations need to be 
maintained at levels equal or above the minimal inhibitory 
concentration (MIC) of the causative micro-organism. It is 
noteworthy that the majority of the patients in this study 
received benzathine penicillin 1.2 MU every four weeks 
as the first prophylactic regimen. With this schedule 
extremely low penicillin concentrations may be present at 
the end of the dosing interval.13 From the literature and also 
the cases presented here, it is suggested that three-weekly 
schedules are more effective for preventing erysipelas. In 
some cases, even two-weekly schedules may be necessary. 
Another approach to provide protective plasma penicillin 
levels is increasing the dosage.14 Doubling the dose 
prolongs the protective plasma penicillin levels by only one 
half-life, which in this case may be around seven days. 
In addition, the deposition of benzathine penicillin after an 
injection in the buttocks has been questioned: the majority 
of injections have been reported to be intralipomatous 
rather than intramuscular.15 Finally, the clinician should 
address the issue of compliance with the prophylactic 
treatment. If oral prophylaxis is being prescribed, 
patient information is a crucial issue. The importance of 
prophylactic treatment to prevent further damage of the 
lymph vessels and serious infections should be stressed.
Importantly, in half of the cases no valid explanation could 
be obtained. Thus, the reasons for failure of prophylaxis in 
the cases remain unclear. The insight that prophylaxis does 
not allow the prevention of all episodes of erysipelas may 
lead to more systematic investigations of this topic.
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